Eribulin

Introduction: What is Eribulin?

Eribulin is a chemotherapy medication primarily used to treat certain types of breast cancer. It is a synthetic derivative of a natural compound found in the sea sponge Halichondria okadai. Approved by the FDA, Eribulin is often prescribed for patients with metastatic breast cancer who have previously undergone multiple treatments. Its unique mechanism of action and effectiveness in specific cancer types make it a valuable option in oncology.

Uses of Eribulin

Eribulin is primarily indicated for:

• Metastatic Breast Cancer: Metastatic or unresectable breast cancer in patients who have previously received at least two chemotherapy regimens, including an anthracycline and a taxane.
• Locally Advanced Breast Cancer: It can be used in patients who are not candidates for surgery or radiation.
• Soft Tissue Sarcoma (Liposarcoma): Approved for patients with unresectable or metastatic liposarcoma who have previously received an anthracycline-containing regimen.

How It Works

Eribulin works by disrupting the normal function of microtubules, which are essential components of the cell's structure and play a critical role in cell division. In simpler terms, it prevents cancer cells from dividing and growing, ultimately leading to their death. By halting the process of cell division, Eribulin effectively slows down or stops the progression of cancer.

Dosage and Administration

Eribulin is administered via injection, typically into a vein (intravenous). The standard dosage for adults is:

• Initial Dose: 1.4 mg/m? of body surface area, given on days 1 and 8 of a 21-day cycle.
• Pediatric Dosage: Safety and efficacy in children have not been established, so it is not typically recommended for pediatric use.

The healthcare provider will determine the exact dosage based on individual patient factors, including overall health and response to treatment.

Side Effects of Eribulin

Common side effects may include:

• Fatigue
• Nausea and vomiting
• Hair loss
• Constipation
• Decreased appetite

Serious side effects can include:

• Febrile neutropenia (low white blood cell count)
• Peripheral neuropathy (numbness or tingling in hands and feet)
• Liver problems
• QT interval prolongation and cardiac rhythm abnormalities

Patients should report any severe or unusual symptoms to their healthcare provider immediately.

Drug Interactions

Eribulin may interact with several medications, including:

• Strong P-glycoprotein (P-gp) inhibitors may increase Eribulin exposure and should be used with caution.
• Other Chemotherapy Agents: Combining Eribulin with certain other chemotherapy drugs may increase the risk of side effects.

Always inform your healthcare provider about all medications and supplements you are taking.

Benefits of Eribulin

The clinical advantages of Eribulin include:

• Efficacy: It has shown effectiveness in patients with heavily pretreated metastatic breast cancer.
• Unique Mechanism: Its distinct action on microtubules offers an alternative for patients who have not responded to other treatments.
• Quality of Life: Some studies suggest Eribulin may help maintain quality of life compared to other late-line chemotherapies.

Contraindications of Eribulin

Eribulin should be avoided in certain populations, including:

• Pregnant Women: It may harm the fetus.
• Patients with Severe Hepatic Impairment: Liver function can affect drug metabolism and increase toxicity.
• Allergic Reactions: Individuals with known hypersensitivity to Eribulin or its components should not use it.

Precautions and Warnings

Before starting Eribulin, patients should undergo:

• Liver Function Tests: To assess liver health.
• Complete Blood Count (CBC): To monitor blood cell levels, especially white blood cells.
• Electrolyte levels and ECG monitoring may be required in patients at risk for QT prolongation.

Patients should also be aware of the potential for severe side effects and discuss any preexisting conditions with their healthcare provider.

FAQs

• What is Eribulin used for? Eribulin is used to treat metastatic breast cancer in patients who have received prior chemotherapy.
• How is Eribulin administered? It is given as an injection into a vein, typically on days 1 and 8 of a 21-day cycle.
• What are the common side effects? Common side effects include fatigue, nausea, hair loss, and constipation.
• Can Eribulin be used in children? Its safety and effectiveness in children have not been established, so it is not typically recommended.
• What should I do if I miss a dose? Contact your healthcare provider for instructions on what to do if you miss a dose.
• Is Eribulin safe during pregnancy? No, Eribulin is contraindicated in pregnant women due to potential harm to the fetus.
• How does Eribulin work? It disrupts microtubule function, preventing cancer cells from dividing and growing.
• What should I tell my doctor before starting Eribulin? Inform your doctor about all medications, supplements, and any preexisting health conditions.
• Can I drink alcohol while taking Eribulin? Alcohol should be consumed with caution, especially in patients with liver dysfunction.
• How often will I need to see my doctor while on Eribulin? Regular follow-up appointments will be necessary to monitor your response to treatment and manage side effects.

Brand Names

Eribulin is marketed under the brand name Halaven.

Conclusion

Eribulin is a significant option in the treatment of metastatic breast cancer, particularly for patients who have exhausted other therapies. Its unique mechanism of action, along with its specific indications and potential side effects, makes it essential for patients and healthcare providers to have thorough discussions about its use. Always consult with a healthcare professional for personalized medical advice.